These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25001469)

  • 1. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
    El-Gamal D; Williams K; LaFollette TD; Cannon M; Blachly JS; Zhong Y; Woyach JA; Williams E; Awan FT; Jones J; Andritsos L; Maddocks K; Wu CH; Chen CS; Lehman A; Zhang X; Lapalombella R; Byrd JC
    Blood; 2014 Aug; 124(9):1481-91. PubMed ID: 25001469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.
    Lu D; Zhao Y; Tawatao R; Cottam HB; Sen M; Leoni LM; Kipps TJ; Corr M; Carson DA
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3118-23. PubMed ID: 14973184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protein kinase C inhibitor AEB071 (sotrastaurin) modulates migration and superoxide anion production by human neutrophils in vitro.
    Capsoni F; Ongari AM; Reali E; Bosè F; Altomare GF
    Int J Immunopathol Pharmacol; 2012; 25(3):617-26. PubMed ID: 23058012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
    Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
    Front Immunol; 2019; 10():2455. PubMed ID: 31681329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.
    Abrams ST; Lakum T; Lin K; Jones GM; Treweeke AT; Farahani M; Hughes M; Zuzel M; Slupsky JR
    Blood; 2007 Feb; 109(3):1193-201. PubMed ID: 17003377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.
    Smith AL; Eiken AP; Skupa SA; Moore DY; Umeta LT; Smith LM; Lyden ER; D'Angelo CR; Kallam A; Vose JM; Kutateladze TG; El-Gamal D
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
    Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
    Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
    Evenou JP; Wagner J; Zenke G; Brinkmann V; Wagner K; Kovarik J; Welzenbach KA; Weitz-Schmidt G; Guntermann C; Towbin H; Cottens S; Kaminski S; Letschka T; Lutz-Nicoladoni C; Gruber T; Hermann-Kleiter N; Thuille N; Baier G
    J Pharmacol Exp Ther; 2009 Sep; 330(3):792-801. PubMed ID: 19491325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.
    Barragán M; Bellosillo B; Campàs C; Colomer D; Pons G; Gil J
    Blood; 2002 Apr; 99(8):2969-76. PubMed ID: 11929788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway.
    Lu D; Liu JX; Endo T; Zhou H; Yao S; Willert K; Schmidt-Wolf IG; Kipps TJ; Carson DA
    PLoS One; 2009 Dec; 4(12):e8294. PubMed ID: 20011538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
    Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
    Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
    Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.